A detailed history of Cresset Asset Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Cresset Asset Management, LLC holds 80,809 shares of IOVA stock, worth $477,581. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,809
Previous 79,943 1.08%
Holding current value
$477,581
Previous $641,000 18.25%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $6,304 - $10,305
866 Added 1.08%
80,809 $758,000
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $69,374 - $126,532
8,917 Added 12.55%
79,943 $641,000
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $43,369 - $99,823
-5,714 Reduced 7.45%
71,026 $1.05 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $102,867 - $277,119
31,172 Added 68.41%
76,740 $623,000
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $58,945 - $116,696
13,276 Added 41.11%
45,568 $207,000
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $6,925 - $11,705
1,292 Added 4.17%
32,292 $227,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $78,680 - $140,000
-14,000 Reduced 31.11%
31,000 $198,000
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $199,825 - $274,890
20,968 Added 87.25%
45,000 $431,000
Q2 2022

Aug 15, 2022

SELL
$6.38 - $18.33 $30,381 - $87,287
-4,762 Reduced 16.54%
24,032 $265,000
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $116,458 - $179,673
9,407 Added 48.52%
28,794 $479,000
Q4 2021

Feb 10, 2022

BUY
$16.55 - $27.63 $8,192 - $13,676
495 Added 2.62%
19,387 $369,000
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $84,940 - $111,153
-4,174 Reduced 18.1%
18,892 $466,000
Q2 2021

Aug 10, 2021

BUY
$16.33 - $33.07 $204,631 - $414,400
12,531 Added 118.95%
23,066 $600,000
Q1 2021

May 12, 2021

BUY
$28.67 - $52.59 $302,038 - $554,035
10,535 New
10,535 $333,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $933M
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Cresset Asset Management, LLC Portfolio

Follow Cresset Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cresset Asset Management, LLC with notifications on news.